In this study we are testing how two drugs, Thymoglobulin ® and verapamil, work together to treat children and young adults with newly diagnosed type 1 diabetes.
In this study we want to learn how a device that automates insulin delivery (called the iLet Bionic Pancreas) helps people with Cystic Fibrosis Related Diabetes manage their insulin levels. We want to learn how well this device works compared to a normal insulin delivery method.
Researchers are trying to find new ways to help improve the mood of teenagers who have Type 2 diabetes (T2D).
This study wants to learn how late menopause affects women. This study wants to see whether diet education, lifestyle changes, and medication can help women feel healthier. We are looking for women ages 45 to 55 who are in late menopause to join.
In this study we are testing a new drug called teplizumab to see if it can help protect the cells that make insulin in people with type 1 diabetes. We want to know if it can improve blood sugar levels, reduce the need for extra insulin, and lower the risk of low blood sugar.
This study wants to see if a new drug called SAB-142 in addition to regular insulin therapy can help slow down Type 1 Diabetes (T1D) in people who were diagnosed in the last 100 days.
To explore the effect of OPT101 treatment on pancreas production in patients with T1DM
In this study we want to learn more about how common health problems like high blood pressure, vision problems, and kidney disease are in people with cystic fibrosis-related diabetes (CFRD).
In this study we want to see if improving the amount and quality of sleep will help improve the overall health of adolescents that have type 1 diabetes (TID).
This study wants to learn more about what causes diabetic neuropathy. Diabetic neuropathy happens when nerves are damaged. We look for certain molecules in the blood and skin that may harm nerves. We compare these molecules in people with Type 2 Diabetes who have neuropathy, people with Type 2 Diabetes who do not have neuropathy, and people who do not have diabetes.
Determine if bone density, bone microarchitecture, and estimates of bone strength change in response to 12 months of glucagon-like peptide-1 receptor agonist (GLP-1 RA)-induced weight loss in pre- and post-menopausal women.
To assess the pharmacodynamic and clinical efficacy of CNP-103
To investigate long-term safety of Sogroya (somapacitan) therapy in patients with AGHD in the setting of routine clinical practice with special focus on neoplasms and diabetes mellitus type 2.
This study is looking for male and female participants with prediabetes that are aged 18 to 64 years old to learn how how short, frequent periods of physical activity impact your health.